Stay updated on Efficacy Safety in Primary IgA Nephropathy Clinical Trial
Sign up to get notified when there's something new on the Efficacy Safety in Primary IgA Nephropathy Clinical Trial page.

Latest updates to the Efficacy Safety in Primary IgA Nephropathy Clinical Trial page
- Check2 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check10 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check17 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. The revision number has also been updated from v2.16.0 to v2.16.1.SummaryDifference2%
- Check24 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.3%
- Check46 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check60 days agoChange DetectedThe page has been updated to reflect a new version of the study protocol for the Nef-301 OLE study, changing from a Phase 3b multicenter study description to an open-label, single-arm study format. Additionally, the name of the study director has been updated to Richard Philipson, MD.SummaryDifference24%
Stay in the know with updates to Efficacy Safety in Primary IgA Nephropathy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Efficacy Safety in Primary IgA Nephropathy Clinical Trial page.